RhumbLine Advisers
MNPR icon

RhumbLine Advisers’s Monopar Therapeutics MNPR Stock Holding History

RhumbLine Advisers’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$521K Buy
5,630
+684
+14% +$42.3K ﹤0.01% 2739
2026
Q1 		$271K Sell
4,946
-44
-0.9% -$2.66K ﹤0.01% 2960
2025
Q4 		$326K Sell
4,990
-298
-6% -$24.3K ﹤0.01% 2922
2025
Q3 		$432K Sell
5,288
-562
-10% -$25.1K ﹤0.01% 2790
2025
Q2 		$209K Buy
+5,850
New +$212K ﹤0.01% 3205

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RhumbLine Advisers's MNPR Position: Q2 2026 in Review

RhumbLine Advisers increased its Monopar Therapeutics (MNPR) stake by 14% in Q2 2026, buying an estimated $42.3K and bringing the position to 5,630 shares worth $521K. The position accounts for ﹤0.01% of the portfolio, ranked #2739.

RhumbLine Advisers first reported a position in MNPR in Q2 2025 and has held it in 5 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • RhumbLine Advisers held 5,630 shares of Monopar Therapeutics worth $521K as of Q2 2026.
  • RhumbLine Advisers bought 684 Monopar Therapeutics shares in Q2 2026, an estimated $42.3K.
  • Monopar Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2739 holding.
  • RhumbLine Advisers first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.